Diversified Trust Co Has $8.33 Million Holdings in Elevance Health, Inc. (NYSE:ELV)

Diversified Trust Co raised its position in shares of Elevance Health, Inc. (NYSE:ELV) by 13.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,576 shares of the company’s stock after acquiring an additional 2,725 shares during the period. Diversified Trust Co’s holdings in Elevance Health were worth $8,328,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Iridian Asset Management LLC CT increased its holdings in Elevance Health by 10.7% during the 3rd quarter. Iridian Asset Management LLC CT now owns 39,154 shares of the company’s stock valued at $20,360,000 after purchasing an additional 3,786 shares in the last quarter. International Assets Investment Management LLC increased its stake in shares of Elevance Health by 85,533.1% in the third quarter. International Assets Investment Management LLC now owns 532,638 shares of the company’s stock valued at $276,972,000 after buying an additional 532,016 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in shares of Elevance Health by 1,711.9% in the third quarter. Benjamin Edwards Inc. now owns 53,559 shares of the company’s stock valued at $27,858,000 after buying an additional 50,603 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Elevance Health by 5.0% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 209,859 shares of the company’s stock worth $109,127,000 after buying an additional 9,916 shares in the last quarter. Finally, Tidal Investments LLC grew its holdings in Elevance Health by 60.6% during the 3rd quarter. Tidal Investments LLC now owns 10,485 shares of the company’s stock worth $5,452,000 after acquiring an additional 3,956 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ELV. Stephens restated an “underperform” rating on shares of Elevance Health in a research report on Friday, October 18th. Cantor Fitzgerald dropped their target price on Elevance Health from $600.00 to $485.00 and set an “overweight” rating for the company in a research report on Friday, October 18th. Mizuho decreased their price target on Elevance Health from $585.00 to $505.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Wells Fargo & Company lowered their price objective on Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, Raymond James set a $485.00 target price on shares of Elevance Health in a research report on Friday, October 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and an average target price of $536.53.

Elevance Health Trading Up 0.3 %

Shares of ELV stock traded up $1.04 on Tuesday, hitting $380.69. The stock had a trading volume of 290,718 shares, compared to its average volume of 1,153,423. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.56. Elevance Health, Inc. has a twelve month low of $362.21 and a twelve month high of $567.26. The company has a fifty day moving average price of $393.67 and a two-hundred day moving average price of $475.68. The firm has a market cap of $88.29 billion, a P/E ratio of 13.88, a PEG ratio of 1.15 and a beta of 0.84.

Elevance Health (NYSE:ELV) last posted its earnings results on Thursday, October 17th. The company reported $8.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.66 by ($1.29). The business had revenue of $44.72 billion during the quarter, compared to analyst estimates of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm posted $8.99 earnings per share. As a group, analysts forecast that Elevance Health, Inc. will post 32.96 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, December 20th. Shareholders of record on Thursday, December 5th were issued a dividend of $1.63 per share. The ex-dividend date of this dividend was Thursday, December 5th. This represents a $6.52 annualized dividend and a yield of 1.71%. Elevance Health’s dividend payout ratio (DPR) is currently 23.77%.

Insider Buying and Selling at Elevance Health

In other news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $432.14, for a total transaction of $3,205,182.38. Following the completion of the transaction, the executive vice president now directly owns 8,423 shares of the company’s stock, valued at $3,639,915.22. This represents a 46.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.35% of the company’s stock.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.